Locations:
SearchTrial outcomes must matter to patients, says Mikkael Sekeres, MD, MS
Mikkael Sekeres, MD, MS, Director of the Leukemia Program at Cleveland Clinic Cancer Center, recently penned an op-ed for ASH Clinical News on the importance of patients in the selection of trial outcomes.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
As editor-in-chief of the news source, Dr. Sekeres argues that many outcomes measured and reported in clinical trials have little to no value to patients in terms of survival or quality of life. He urges fellow clinicians to take Robert Frost’s “road less traveled” while using the Cleveland Browns abysmal 2016 record to identify flaws in oncology outcomes measures.
Read the full editorial here.
Advertisement
Advertisement
Timing and type of side effects differ greatly from chemotherapy
Dedicated multidisciplinary teams support 84 ultra-rare cancers
Sessions explore treatment advances and multidisciplinary care
New research from Cleveland Clinic helps explain why these tumors are so refractory to treatment, and suggests new therapeutic avenues
Combination of olaparib and carboplatin results in complete durable response for a patient with BRCA2 and “BRCAness” mutations
Early communication between oncologists and ophthalmologist warranted
Case-based course delves into latest treatment approaches
Long-term relationship building and engagement key to gaining community trust